Another study demonstrated that the inhibition of BRD9 acted in a synthetic lethal manner in cBAF-deficient cancer, and the inhibitor of BRD9 effectively decreased the proliferation of cancer cells in synovial sarcoma and malignant rhabdoid tumors [25]. The gene discussed is BRD9; the disease is rhabdoid tumor.